Abstract
Realgar has been used successfully to treat diseases for thousands of years, but its poor water solubility and high toxicity hampered its further medical uses. Here, we first applied transdermal drug delivery system to deliver realgar nanoparticles to investigate its anticancer effect and toxicity in vivo. In this study, MTT assay and flow cytometry analysis demonstrated that realgar significantly suppressed the proliferation and induced apoptosis of B16 melanoma cells in a dose-dependent manner. Transdermal penetration studies in vitro showed realgar nanoparticles could be delivered efficiently through skin. Tests on tumor-bearing C57BL/6 mice displayed that realgar could decrease the tumor volume markedly via transdermal drug delivery compared with the intraperitoneal administration and the control. Hematoxylin–eosin and immunohistochemical staining revealed that it could inhibit angiogenesis. The monitoring of the hepatic injury, body weight, feeding behavior, motor activity, and skin irritation of each animal indicated little toxicity of realgar to mice. The results demonstrated that realgar nanoparticles can be dermally delivered to achieve high efficacy against menaloma in vivo with low toxicity.
Similar content being viewed by others
References
Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179–85. doi:10.1111/j.1365-2133.2004.05708.x.
Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. doi:10.3322/canjclin.57.1.43.
Yang L, Parkin DM, Ferlay J, Li L, Chen YD. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 2005;14:243–50. doi:10.1158/1055-9965.EPI-04-0680.
Anonymous. The inner canon of Emperor Huang. Beijing: Chinese Medical Ancient Books Publishing House; 2003.
The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet, Qian LS, Zhao YZ. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol. 2006;27:801–4.
Frankenberger WT. Environmental chemistry of arsenic. 1st ed. New York: Marcel Dekker Inc; 2002.
Lu DP, Wang Q. Current study of APL treatment in China. Int J Hematol. 2002;76:316–8.
Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136–43. doi:10.1182/blood.V99.9.3136.
Zhu J, Chen Z, Lallemand-Breitenbach V, de The′ H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705–13. doi:10.1038/nrc887.
Deng Y, Xu HB, Huang KX, Yang XL, Xie CS, Wu J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ecv-304. Pharmacol Res. 2001;44:513–8. doi:10.1006/phrs.2001.0885.
Wang XB, Xi RG, Zhang ZR, Wang JG, Yao W. Study on pharmacokinetics of nanoparticle realgar powders in rabbit (in Chinese). Pharmaceutical J PLA. 2002;18:324–6.
Liu J, Lu YF, Wu Q, Goyer RA, Waalkes MP. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmaco Exp Ther. 2008;326:363–8. doi:10.1124/jpet.108.139543.
Hu J, Fang J, Dong Y, Chen SJ, Chen Z. Arsenic in cancer therapy. Anti-cancer Drug. 2005;16:119–26. doi:10.1097/00001813-200502000-00002.
Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3:115–24. doi:10.1038/nrd1304.
Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today. 2004;9:697–703. doi:10.1016/S1359-6446(04)03180-0.
Kung AL, Wang S, Klco JM, Kaelin WG, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000;6:1335–40. doi:10.1038/82146.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273–86. doi:10.1038/nrd2115.
Peter V, Oliver T, Michael H. Treatment resistance of solid tumors. Med Oncol. 2001;18:243–59. doi:10.1385/MO:18:4:243.
Keshet E, Ben-Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Invest. 1999;104:1497–501. doi:10.1172/JCI8849.
Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677–84. doi:10.1038/nm0603-677.
Bocci G, Falcone A, Fioravanti A, Orlandi P, Paolo AD, Fanelli G, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008;98:1619–29. doi:10.1038/sj.bjc.6604352.
Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci. 2006;29:35–44. doi:10.1016/j.ejps.2006.05.002.
Luo LY, Huang J, Gou BD, Zhang TL, Wang K. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: Involvement of serine/threonine protein phosphatases. Leukemia Res. 2006;30:1399–405. doi:10.1016/j.leukres.2006.03.016.
Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, et al. An integrated approach to measuring tumor oxygen status using human melanoma Xenografts as a model. Cancer Res. 2003;63:7232–40.
Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002;1:1243–53.
Selvakumaran M, Yao KS, Feldman MD, O’Dwyer PJ. Anticancer effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627–38. doi:10.1016/j.bcp.2007.09.029.
Tse WP, Che CT, Ken L, Lin ZX. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol. 2006;108:133–41. doi:10.1016/j.jep.2006.04.023.
Ding HF, Fisher DE. Induction of apoptosis in cancer: new therapeutic opportunities. Ann Med. 2002;34:451–69. doi:10.1080/078538902321012405.
Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008;259:39–49. doi:10.1016/j.canlet.2007.09.015.
Jiang XH, Wong BCY, Yuen ST, Jiang SH, Cho CH, Lai KC, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer. 2001;15:173–9. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1039>3.0.CO;2-D.
YM Li, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59:776–80.
Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, et al. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000;60:3065–7301.
Leung J, Pang A, Yuen WH, Kwong YL, Tse EWC. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007;109:740–6. doi:10.1182/blood-2006-04-019588.
Sintov AC, Wormser U. Topical iodine facilitates transdermal delivery of insulin. J Control Release. 2007;118:185–8. doi:10.1016/j.jconrel.2006.12.006.
Marie V. Mechanisms of arsenic biotransformation. Toxicology. 2002;181:211–7. doi:10.1016/S0300-483X(02)00285-8.
Acknowledgments
This work was supported in part by grants from the Chinese Ministry of Sciences 973 Program (2006CB933300, 2007CB935800), Natural Science Foundation of China (#30721002), Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-139), the Cultivation Fund of the Ministry of Education of China (NO706035), and a grant from the science and technology key project of Anhui Province (07010302183).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhao, QH., Zhang, Y., Liu, Y. et al. Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med Oncol 27, 203–212 (2010). https://doi.org/10.1007/s12032-009-9192-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-009-9192-1